含米托蒽醌方案治疗恶性肿瘤97例的近期疗效与毒性  

Effect and Toxicity of Mitoxantrone Contained Regimen irl the Treatment of Malignancies

作　　者：翁方纪 马菊颖[2] 朱松英 陈唤青[4] 毛玉文 龚皓 龚振夏[7] 蔡浩[2] 

机构地区：[1]浙江省德清县第一医院,德清县313200 [2]浙江省肿瘤医院 [3]117医院 [4]南通医学院附院 [5]无锡市一院 [6]武汉市一院 [7]南通肿瘤医院

出　　处：《中国肿瘤临床》1993年第11期861-864,共4页Chinese Journal of Clinical Oncology

摘　　要：本文采用含Mx方案治疗恶性肿瘤97例,完全缓解27例,部分缓解30例,总有效率58.7％。其中急性白血病44例有效率63.6％,ALL69.2％(9/13),AML67.8％(19/28)。实体瘤有效率54.7％,恶性淋巴瘤 75％(12/16),乳癌 47％(8/17),肺癌 40％(6/15)。Mx的血液毒性较重,白细胞,血小板,血红蛋白减少发生率分别为69％,27％与47.4％。非血液毒性较轻,Ⅰ-Ⅱ°居多,未见严重心脏毒性与不可逆的毒性反应。提示Mx为一强效、广谱抗肿瘤药物。A Mitoxantrone contained regimen was und in treating 97 cases of malignant tumors and achieved an overall responsive rate of 58.7％ with 27％ CRs and 30 PRs. The RRs were 63. 6％ for acute leukemias and 54.7％for solid tumors. In cases of malignant lymphoma, breast cancers and lung cancers the respective responsive rates were 25％, 47％and 40％in that order. Haematologic side effects were considerably noteworthy with declining of leucocyte, platelet and hemoglobin in 69％, 27％ and 47. 4 ％ respectively. Whereas non-hemotologic side effects were mild, with Ⅰ°- Ⅱ° prevailing, and no serious heart toxicity nor irreversible adverse reactions were encountered. In consequence mitoxantrone is a higher potent anticancer agent with broad spectrum of target tumors.

关 键 词：米托蒽醌 肿瘤 毒性 癌 

分 类 号：R730.53[医药卫生—肿瘤]